Boehringer Ingelheim has inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.

Biopharmaceuticals are highly complex drugs and at the same time one of the fastest growing drug segments of the pharmaceutical industry. They offer therapies for many indications such as cancer, stroke or heart attack.

The new facility is a highly complex building, offering modern workplaces for more than 500 employees who will develop Boehringer Ingelheim's future biopharmaceutical substances. Scientists from multiple disciplines and three different development units will collaborate under one roof to research and develop antibodies and therapeutic proteins. They will have the capability to produce these substances from lab-scale to supply for clinical studies.

This inauguration is another milestone in the further development of Boehringer Ingelheim’s campus in Biberach, which is the company’s largest R&D and Biopharmaceuticals site with more than 7,000 employees. The construction of the BDC is part of Boehringer Ingelheim's consistent future strategy with significant investments in its R&D pipeline, which amounted to 5 billion EUR in the last business year – 47 percent alone in Germany.